( -- Data from Phase III pivotal trial de...)Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007,Health

NAPA, Calif., May 16, 2007 /PRNewswire/ -- Dey, L.P. announced that two clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on Sunday, May 20, at the Moscone Center in San Francisco. The presentations will detail Phase III clinical data demonstrating the safety and efficacy of Perforomist(TM) (formoterol fumarate) Inhalation Solution, approved on May 11 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

    For those attending ATS, the two presentations are available as follows:


    -- "Nebulized Formoterol is an Effective Bronchodilator and Improves the

       Quality of Life for COPD Patients," Poster Board #A10, Publ. pg. A128.

    -- "Safety Profile of Formoterol Fumarate Delivered by Nebulization to

       COPD Patients," Poster Board #A11, Publ. pg. A128


    Poster Viewing: 10:45 AM - 12:15 PM

    Room: Area A (Hall D, Lower Level), Moscone Center

Session Info: Thematic Poster Session, [A47] COPD Treatment I: Bronchodilators, Inhaled Corticosteroids and PDE4 Inhibitors.

Please note that the principal investigators will be available to discuss the research results.

About COPD

COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes increasingly difficult. The most common forms of COPD are chronic bronchitis and emphysema, and many patients suffer from a combination of the two diseases.

According to the National Heart, Lung and Blood Institute of the National Institutes of Health, COPD is the fourth leading cause of death in America, behi
'"/>